Total Payments
$16,192
2024 Payments
$2,065
Companies
50
Transactions
1,106
Medicare Patients
8,944
Medicare Billing
$392,756
Payment Breakdown by Category
Food & Beverage$15,971 (98.6%)
Education$221.39 (1.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $15,971 | 1,100 | 98.6% |
| Education | $221.39 | 6 | 1.4% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Janssen Pharmaceuticals, Inc | $2,544 | 243 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $1,989 | 133 | $0 (2024) |
| Amgen Inc. | $1,591 | 108 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $949.17 | 64 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $826.64 | 46 | $0 (2023) |
| SANOFI-AVENTIS U.S. LLC | $813.63 | 55 | $0 (2024) |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $750.14 | 52 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $705.70 | 57 | $0 (2024) |
| PFIZER INC. | $705.10 | 48 | $0 (2024) |
| Merck Sharp & Dohme LLC | $611.84 | 33 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,065 | 113 | Novartis Pharmaceuticals Corporation ($339.01) |
| 2023 | $1,815 | 105 | Novartis Pharmaceuticals Corporation ($207.52) |
| 2022 | $2,412 | 158 | Novartis Pharmaceuticals Corporation ($390.05) |
| 2021 | $2,489 | 175 | Janssen Pharmaceuticals, Inc ($444.49) |
| 2020 | $1,725 | 128 | Janssen Pharmaceuticals, Inc ($616.13) |
| 2019 | $1,667 | 124 | Janssen Pharmaceuticals, Inc ($350.88) |
| 2018 | $2,285 | 156 | Amgen Inc. ($320.23) |
| 2017 | $1,734 | 147 | Janssen Pharmaceuticals, Inc ($370.00) |
All Payment Transactions
1,106 individual payment records from CMS Open Payments — Page 1 of 45
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $15.30 | General |
| Category: Cardiology | ||||||
| 12/17/2024 | Actelion Pharmaceuticals US, Inc. | OPSUMIT (Drug), UPTRAVI | Food and Beverage | In-kind items and services | $13.05 | General |
| Category: Cardiology | ||||||
| 12/11/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $19.86 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 12/10/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $20.22 | General |
| Category: CARDIOVASCULAR | ||||||
| 12/09/2024 | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | LifeVest (Device) | Food and Beverage | Cash or cash equivalent | $17.32 | General |
| Category: Electromedical and Electrotherapeutic Apparatus | ||||||
| 12/05/2024 | SCPHARMACEUTICALS INC. | FUROSCIX (Drug) | Food and Beverage | In-kind items and services | $21.72 | General |
| Category: Cardiology | ||||||
| 12/04/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $16.80 | General |
| Category: Cardiovascular | ||||||
| 11/26/2024 | CVRx, Inc. | Barostim Neo System (Device) | Food and Beverage | Cash or cash equivalent | $15.19 | General |
| Category: Heart Failure and Hypertension | ||||||
| 11/26/2024 | Actelion Pharmaceuticals US, Inc. | OPSUMIT (Drug), UPTRAVI | Food and Beverage | In-kind items and services | $15.11 | General |
| Category: Cardiology | ||||||
| 11/22/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $30.35 | General |
| Category: CARDIOVASCULAR | ||||||
| 11/18/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $14.84 | General |
| Category: DIABETES | ||||||
| 11/12/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $18.96 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 11/05/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $16.19 | General |
| Category: Cardiology | ||||||
| 10/30/2024 | Alnylam Pharmaceuticals Inc. | ONPATTRO (Drug) | Food and Beverage | In-kind items and services | $21.85 | General |
| Category: Genetic Disease | ||||||
| 10/30/2024 | Actelion Pharmaceuticals US, Inc. | OPSUMIT (Drug), UPTRAVI | Food and Beverage | In-kind items and services | $15.27 | General |
| Category: Cardiology | ||||||
| 10/24/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $20.49 | General |
| Category: CARDIOVASCULAR | ||||||
| 10/24/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $15.31 | General |
| Category: Cardio-renal | ||||||
| 10/22/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $15.75 | General |
| Category: Cardiovascular | ||||||
| 10/17/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug), LEQVIO | Food and Beverage | In-kind items and services | $14.55 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 10/01/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $16.63 | General |
| Category: Cardiology | ||||||
| 09/26/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $21.04 | General |
| Category: CARDIOVASCULAR | ||||||
| 09/25/2024 | Actelion Pharmaceuticals US, Inc. | OPSUMIT (Drug), UPTRAVI | Food and Beverage | In-kind items and services | $14.59 | General |
| Category: Cardiology | ||||||
| 09/24/2024 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $21.92 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 09/19/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $19.06 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 09/17/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $21.78 | General |
| Category: DIABETES | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 21 | 2,127 | 2,394 | $343,065 | $86,189 |
| 2022 | 24 | 2,262 | 2,562 | $377,456 | $96,622 |
| 2021 | 25 | 2,415 | 2,761 | $415,744 | $119,302 |
| 2020 | 23 | 2,140 | 2,447 | $342,294 | $90,643 |
Total Patients
8,944
Total Services
10,164
Medicare Billing
$392,756
Procedure Codes
93
All Medicare Procedures & Services
93 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 169 | 223 | $61,102 | $18,787 | 30.7% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Facility | 2023 | 352 | 360 | $79,920 | $17,844 | 22.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 198 | 239 | $45,888 | $12,835 | 28.0% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 79 | 150 | $23,100 | $8,326 | 36.0% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 63 | 65 | $18,785 | $5,757 | 30.6% |
| 93010 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | Facility | 2023 | 484 | 551 | $22,591 | $3,318 | 14.7% |
| 78452 | Nuclear medicine studies of heart muscle at rest and with stress and spect | Facility | 2023 | 66 | 66 | $14,850 | $3,141 | 21.2% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 25 | 32 | $7,072 | $2,618 | 37.0% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 19 | 19 | $8,113 | $2,330 | 28.7% |
| 93312 | Ultrasound of heart with probe in esophagus, with report | Facility | 2023 | 25 | 27 | $9,234 | $2,081 | 22.5% |
| 93016 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | Facility | 2023 | 127 | 128 | $8,832 | $1,834 | 20.8% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 179 | 187 | $10,285 | $1,681 | 16.3% |
| 92960 | External shock to heart to regulate heart beat | Facility | 2023 | 19 | 19 | $12,787 | $1,519 | 11.9% |
| 93018 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | Facility | 2023 | 126 | 127 | $5,842 | $1,210 | 20.7% |
| 93351 | Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | Facility | 2023 | 16 | 16 | $4,240 | $886.59 | 20.9% |
| 93308 | Ultrasound of heart, follow-up | Facility | 2023 | 43 | 44 | $3,520 | $803.67 | 22.8% |
| 93320 | Ultrasound of heart blood flow, valves and chambers | Facility | 2023 | 35 | 36 | $2,052 | $454.58 | 22.2% |
| 93880 | Ultrasound of both sides of head and neck blood flow | Facility | 2023 | 12 | 12 | $1,452 | $336.42 | 23.2% |
| 93321 | Ultrasound of heart blood flow, valves and chambers, follow-up | Facility | 2023 | 43 | 44 | $1,012 | $228.76 | 22.6% |
| 99152 | Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | Facility | 2023 | 12 | 13 | $2,028 | $118.04 | 5.8% |
| 93325 | Ultrasound of heart with color-depicted blood flow, rate and valve function | Facility | 2023 | 35 | 36 | $360.00 | $79.56 | 22.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 203 | 259 | $70,966 | $21,083 | 29.7% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Facility | 2022 | 367 | 376 | $83,472 | $19,549 | 23.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 213 | 249 | $47,808 | $12,928 | 27.0% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 71 | 156 | $24,024 | $8,060 | 33.5% |
About Dr. Charles Mathis, MD
Dr. Charles Mathis, MD is a Cardiovascular Disease healthcare provider based in Elkhart, Indiana. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/09/2005. The National Provider Identifier (NPI) number assigned to this provider is 1326042029.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Charles Mathis, MD has received a total of $16,192 in payments from pharmaceutical and medical device companies, with $2,065 received in 2024. These payments were reported across 1,106 transactions from 50 companies. The most common payment nature is "Food and Beverage" ($15,971).
As a Medicare-enrolled provider, Mathis has provided services to 8,944 Medicare beneficiaries, totaling 10,164 services with total Medicare billing of $392,756. Data is available for 4 years (2020–2023), covering 93 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Location Elkhart, IN
- Active Since 06/09/2005
- Last Updated 05/01/2023
- Taxonomy Code 207RC0000X
- Entity Type Individual
- NPI Number 1326042029
Products in Payments
- XARELTO (Drug) $2,544
- ENTRESTO (Drug) $1,607
- ELIQUIS (Drug) $1,113
- Repatha (Biological) $951.31
- JARDIANCE (Drug) $765.93
- LifeVest (Device) $750.14
- BRILINTA (Drug) $644.92
- Corlanor (Drug) $639.23
- VERQUVO (Drug) $611.84
- MULTAQ (Drug) $561.79
- NEXLETOL (Drug) $471.69
- LEQVIO (Drug) $381.91
- ONPATTRO (Drug) $315.99
- Kerendia (Drug) $287.49
- PRALUENT (Drug) $251.84
- WATCHMAN Access System (Device) $223.02
- OPSUMIT (Drug) $216.68
- Verquvo (Drug) $176.89
- PRADAXA (Drug) $172.20
- KENGREAL (Drug) $162.71
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in Elkhart
Dr. Gurudutt Kulkarni, M.d, M.D
Cardiovascular Disease — Payments: $27,816
Cardiovascular Disease $27,816
Adil Wani, Md, MD
Cardiovascular Disease — Payments: $25,103
Cardiovascular Disease $25,103
Dr. Luisito Gonzales, M.d, M.D
Cardiovascular Disease — Payments: $14,984
Cardiovascular Disease $14,984
Nazmul Huda, Md, MD
Cardiovascular Disease — Payments: $14,881
Cardiovascular Disease $14,881
Dr. Paul Cheng, Md, MD
Cardiovascular Disease — Payments: $3,859
Cardiovascular Disease $3,859